A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

This trial has a duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.

开始日期2026-04-01

申办/合作机构

Ascendis Pharma Bone Diseases A/S

CTIS2025-523928-52-00

/ Not yet recruiting临床3期

PaTHway Adolescent - A Phase 3, Multicenter, Open-Label Single-Arm Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Palopegteriparatide Administered Subcutaneously Daily in the Adolescent Population (12 Years to Less Than 18 Years of Age) with Chronic Hypoparathyroidism

开始日期2026-03-31

申办/合作机构

Ascendis Pharma Bone Diseases A/S

NCT07345494

/ RecruitingN/A

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.

开始日期2026-02-18

申办/合作机构

Ascendis Pharma A/S

100 项与帕罗培特立帕肽相关的临床结果

登录后查看更多信息

100 项与帕罗培特立帕肽相关的转化医学

登录后查看更多信息

100 项与帕罗培特立帕肽相关的专利（医药）

登录后查看更多信息

6,663

项与帕罗培特立帕肽相关的文献（医药）

2026-05-01·Journal of Orthopaedics

Teriparatide enhances vertebral bone quality: Quantitative analysis using the VBQ score in lumbar fusion patients

Article

作者: Sako, Noriaki ; Abe, Tetsutaro ; Miyazaki, Masashi ; Kaku, Nobuhiro

Background:

Vertebral bone quality is a critical factor influencing spinal stability and surgical planning. The vertebral bone quality (VBQ) score, derived from routine MRI, has emerged as a noninvasive imaging biomarker of bone quality; however, its clinical implications in the perioperative spinal fusion setting remain incompletely understood.

Methods:

This retrospective study included patients who underwent single-level lumbar fusion at L4-5. VBQ was measured at T12-L2 to avoid instrumentation-related artifacts. Associations between VBQ and radiographic parameters were evaluated using correlation and multivariable regression analyses. Inter- and intra-rater reliability were assessed using kappa statistics.

Results:

VBQ scores significantly decreased in the PTH group (ΔVBQ -0.31 ± 0.56), indicating improved bone quality, whereas no improvement was observed in controls (ΔVBQ 0.08 ± 0.61; p = 0.03). HU changes did not differ between groups. ΔVBQ correlated with postoperative BMD (r = -0.28, p = 0.04) and PTH duration (r = -0.39, p = 0.01). Regression analysis identified PTH use (β = -0.39, 95%CI: -0.72 to -0.06, p = 0.02) and treatment duration (β = -0.27, 95%CI: -0.52 to -0.02, p = 0.03) as independent predictors of VBQ improvement with R² of 0.32.

Conclusion:

Perioperative teriparatide significantly enhances vertebral bone quality, demonstrated by reduced VBQ scores over 12 months. VBQ appears more sensitive than HU or BMD to anabolic therapy-induced qualitative changes and may serve as a practical imaging biomarker for optimizing perioperative bone management in osteoporotic spinal fusion patients.

2026-04-01·VETERINARY JOURNAL

Markers of bone turnover, parathyroid hormone, calcium, and magnesium concentrations in horses with acute colitis

Article

作者: Gomez, Diego E ; Toribio, Ramiro E ; Fortin-Trahan, Rosalie ; Arroyo, Luis G ; Hostnik, Laura D ; Kamr, Ahmed

Hypocalcemia is frequent in horses with colitis. Information on serum parathyroid hormone (PTH) concentrations and its association with bone turnover biomarkers in horses with colitis is lacking. We aimed to determine the association between serum bone resorption biomarkers (C-terminal telopeptide of type I collagen [CTX-I]) and bone formation (osteocalcin [OCN]) with blood PTH, total calcium (tCa), ionized calcium (iCa), phosphorus (Pi), and total magnesium (tMg) concentrations, and mortality in horses with acute colitis. A total of 163 horses were divided into colitis (n = 127) and healthy (n = 36) groups. Blood samples were collected from all horses. Non-parametric methods were used for data analysis. In horses with colitis, serum CTX-I and PTH concentrations were significantly higher, whereas OCN, tCa, iCa, Pi, and tMg concentrations were lower compared to healthy horses (P < 0.05). In colitis horses with ionized hypocalcemia, serum CTX-I concentrations were positively correlated with PTH concentrations (P < 0.05). Colitis horses with iCa concentrations < 1.4 mmol/L and PTH > 92.9 pg/mL were more likely to die ([OR = 6.1; 95 % CI = 1.2-24.5; P < 0.05]; [OR = 3.6; 95 % CI = 1.3-10.1; P < 0.05]), respectively. In colitis horses, elevated PTH and CTX-I concentrations, together with decreased OCN concentrations, suggests that bone turnover activity was increased to offset hypocalcemia. Elevated PTH and hypocalcemia were associated with non-survival, indicating that in non-surviving horses, bone resorption activity was not sufficient to restore normocalcemia. PTH resistance could have contributed to hypocalcemia in some horses with acute colitis.

2026-04-01·CLINICA CHIMICA ACTA

Validation of parathyroid hormone measurement in fine-needle aspiration biopsy washings according to the IFCC LEAP checklist

Article

作者: Kumorek, Aleksandra ; Ciepiela, Olga ; Chudziński, Witold ; Kozłowska, Ewa

BACKGROUND:

Measurement of parathyroid hormone in fine-needle aspiration biopsy washings (FNAB-PTH) is widely used in clinical practice to confirm parathyroid tissue origin and support lesion localization, particularly when imaging findings are inconclusive. However, comprehensive analytical validation of FNAB-PTH according to the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Laboratory Evaluation and Analytical Performance (LEAP) framework has not been performed for this non-standard matrix.

METHODS:

FNAB washings were analyzed using the Elecsys PTH assay on the cobas platform. Analytical performance was evaluated in accordance with the IFCC LEAP framework, including precision, linearity, limits of detection and quantification, carryover, matrix effects, stability, and robustness. Results obtained in 0.9% saline were compared with measurements after supplementation with a protein-based diluent. Clinical performance was assessed by comparison with histopathology, which served as the reference standard.

RESULTS:

FNAB-PTH demonstrated excellent precision (CV ≤10%), preserved linearity, negligible carryover, and acceptable analytical sensitivity. A pronounced concentration-dependent matrix effect was observed in saline washings, with median recovery increasing from 46.9% at low to 76.5% at high PTH concentrations; this effect was markedly reduced after protein supplementation. PTH in FNAB washings remained stable under routine preanalytical conditions, although reduced stability was observed in high-concentration samples during prolonged storage. In 100 cases, FNAB-PTH showed high agreement with histopathology (overall agreement 89.0%).

CONCLUSIONS:

Analytical validation of FNAB-PTH according to the IFCC LEAP framework confirms good analytical quality and supports its clinical utility for confirming parathyroid tissue origin and assisting lesion localization, despite the presence of a concentration-dependent matrix effect.

238

项与帕罗培特立帕肽相关的新闻（医药）

2026-03-23

·Science Daily

Scientists discover hormone that may stop chronic back pain at its source

A new study suggests a widely used bone hormone could help relieve chronic back pain in an unexpected way. Instead of just strengthening bone, it appears to stop pain-sensing nerves from growing into damaged spinal areas. In animal models, this led to stronger spinal tissue and reduced pain sensitivity. The findings hint at a future treatment that tackles back pain at its biological roots.Low back pain (LBP) is one of the most widespread health issues globally, affecting people across all age groups and putting significant strain on healthcare systems. For many, the pain becomes long-lasting, disrupting work, sleep, and everyday life. In most cases, however, doctors cannot pinpoint a clear structural cause, which makes effective long-term treatment challenging. A new study published in Volume 14 of the journal Bone Research suggests that a hormone-based treatment could help ease chronic back pain by reducing abnormal nerve growth within damaged spinal tissue. The research was led by Dr. Janet L. Crane from the Center for Musculoskeletal Research, Department of Orthopedic Surgery, Johns Hopkins University School of Medicine, United States. The findings offer new insight into how bone cells may influence pain signaling in degenerating spines. "During spinal degeneration, pain-sensing nerves grow into regions where they normally do not exist. Our findings show that parathyroid hormone can reverse this process by activating natural signals that push these nerves away," says Dr. Crane. Understanding Parathyroid Hormone and Its Effects Parathyroid hormone (PTH) is naturally produced by the parathyroid glands and plays a key role in regulating calcium levels and bone remodeling. Synthetic versions of PTH are already used to treat osteoporosis. Earlier research hinted that these treatments might also reduce bone-related pain, but the underlying biological mechanism was not well understood. To explore this further, the research team used three mouse models that replicate common causes of spinal degeneration: natural aging, surgically induced mechanical instability, and genetic susceptibility. These models allowed scientists to study how degeneration affects both bone structure and nerve growth. The mice received daily injections of PTH for periods ranging from two weeks to two months, while control animals were given inactive solutions. Researchers then examined spinal tissue using high-resolution imaging and measured responses to pressure, heat, and movement. Improved Spine Structure and Reduced Pain Sensitivity After one to two months of treatment, mice treated with PTH showed clear improvements in their vertebral endplates, the thin layers that separate spinal discs from vertebrae. These structures became denser and more stable. At the same time, treated mice showed reduced sensitivity to pain, tolerated pressure better, responded more slowly to heat, and displayed increased activity compared to untreated animals. How PTH Reduces Pain-Causing Nerve Growth The researchers also examined nerve fibers within the spine. In damaged tissue, pain-sensing nerves often extend into areas where they do not typically belong, increasing discomfort. The study found that PTH treatment significantly reduced these abnormal nerve fibers, based on markers such as PGP9.5 and CGRP. Further analysis revealed the underlying mechanism. PTH stimulated osteoblasts, the cells responsible for building bone, to produce a protein called Slit3. This protein acts as a guidance signal that repels growing nerve fibers, preventing them from entering sensitive regions of the spine. Slit3 Protein and the Molecular Pathway Laboratory experiments confirmed that Slit3 directly limits nerve growth. When nerve cells were exposed to Slit3, their extensions became shorter and less invasive. In contrast, when researchers removed Slit3 from osteoblasts in mice, PTH no longer reduced nerve growth or improved pain responses. The team also identified a regulatory protein called FoxA2 that helps trigger Slit3 production in response to PTH, offering deeper insight into how hormonal signals influence nerve behavior. What This Means for Future Back Pain Treatments Although these findings come from animal studies, they may help explain why some patients receiving PTH-based treatments for osteoporosis report reduced back pain. The researchers note that further studies in humans are needed before this approach can be used clinically. "Our study suggests that PTH treatment of LBP during spinal degeneration may reduce aberrant innervation, laying the foundation for future clinical trials exploring the efficacy of PTH as a disease-modifying and pain-relief treatment for spinal degeneration," concludes Dr. Crane. About the Researcher Dr. Janet L. Crane is an Associate Professor of Pediatrics at the Johns Hopkins University School of Medicine, United States where she serves as the Director of the Pediatric Bone Health Program. She also holds a joint appointment in the Center for Musculoskeletal Research in the Department of Orthopedic Surgery. She earned her bachelor's degree in nutritional science from the University of Missouri and completed her medical degree at the University of Maryland-Baltimore. Her research focuses on metabolic bone diseases and skeletal fragility, and she has published extensively on bone remodeling, metabolic bone disorders, and skeletal pain mechanisms. This research was supported by the U.S. Department of Health & Human Services NIH National Institute on Aging under Award Number P01AG066603 (to Xu Cao), Sub-Project 6878 (to Janet Crane).

2026-03-20

·研发客

Revolution、Ascendis，谁会被收购？

加拿大皇家银行资本市场（RBC Capital Markets）近期发布最新研报，筛选出13家具备高收购价值的生物技术核心收购标的，其中肿瘤药企Revolution Medicines与内分泌罕见病药企Ascendis Pharma位列前两位。 Revolution是RAS赛道的标杆企业，当前市值195亿美元，近一年股价涨幅高达156%。公司核心管线daraxonrasib是一款泛RAS抑制剂，在胰腺癌领域竞争力强劲，其单药用于胰腺癌二线治疗的客观缓解率（ORR）为29%，一线治疗ORR更是达到47%，凭借优异临床数据获得了FDA颁发的国家优先审评券（CNPV）。今年1月，市场传出默沙东正与该公司洽谈收购，交易规模或超300亿美元，不过该笔交易目前仍未落地。 Ascendis则专注内分泌罕见病药物研发，市值140亿美元，近一年股价上涨38%。公司业绩增长态势亮眼，2025年总营收7.2亿欧元，同比增长98%，其中两款商业化产品Yorvipath（帕罗培特立帕肽）和Skytrofa（隆培生长激素）是业绩增长的主要贡献者。此外，上榜企业还包括siRNA领域的头部企业Arrowhead Pharmaceuticals，拥有全球首个进入临床的TRiM™ Dimer单分子双功能RNAi双靶点技术，管线涉及肥胖、阿尔茨海默病等高值赛道；CNS企业Xenon Pharmaceuticals近期凭借抗癫痫药物azetukalner的关键III期临床（X-Tole2）顶线数据获得市场关注。 RBC在研报中还指出，默沙东、百时美施贵宝、渤健、艾伯维、Vertex、再生元、Jazz制药、Acadia是近期的核心潜在买家。总第2810期访问研发客网站www.PharmaDJ.com 深度报道和每日新闻抢鲜看

临床3期优先审批并购siRNA引进/卖出

2026-03-16

·化工邦学堂

蛋白多肽类药物长效化技术研究进展

▌化工邦学堂，会议论坛全知晓资讯干货随心找多肽修饰种类繁多，从修饰位点不同则可分为N端修饰、C端修饰、侧链修饰、氨基酸修饰、骨架修饰等。作为一种改变肽链主链结构或侧链基团的重要手段，多肽修饰可有效改变肽类化合物的理化性质、增加水溶性、改变其生物分布状况、延长体内作用时间、降低毒副作用、消除免疫原性等。侧链修饰是最常用的长效修饰方法。多肽复杂侧链修饰是指对多肽分子中氨基酸侧链的功能基团进行选择性化学改造，以调控其物理化学性质、生物活性或功能特性。这一策略在多肽药物开发、分子探针设计及功能材料构建中至关重要，尤其适用于天然多肽存在稳定性差、半衰期短或靶向性不足等局限时。‌ chem-bang 01 长效多肽药物侧链的作用机理 1、药效动力学调控机制‌ 多肽长效化侧链通过延缓药物代谢与排泄，显著延长血浆半衰期。例如，脂肪酸侧链可促进药物与血清白蛋白结合，形成“储库效应”，使药物释放周期从数小时延长至数周‌。聚乙二醇（PEG）侧链通过增大分子量减少肾小球滤过率，同时形成空间位阻降低酶解速率‌。 ‌2、分子稳定性增强路径‌ 侧链修饰可抑制多肽分子构象变化：‌多肽侧链修饰通过引入化学基团改变侧链性质，从而抑制构象变化，增强结构稳定性。其机理主要涉及‌空间位阻效应、稳定关键相互作用和引入共价约束‌。 ‌空间位阻效应‌：修饰基团（如聚乙二醇或脂肪酸链）引入后占据空间，阻碍主链旋转或侧链摆动，限制构象自由度，例如脂肽修饰通过疏水链增强分子内相互作用减少无序波动。 ‌ 稳定氢键网络或疏水核心‌：修饰如磷酸酯或糖基化可优化侧链极性，增强分子内氢键或疏水堆积，维持折叠状态，例如糖肽修饰通过水化层稳定二级结构。 ‌ 形成共价约束‌：如二硫键或环化修饰，直接连接侧链或末端，固定空间取向，例如侧链-侧链环化通过酰胺键锁定β-折叠或α-螺旋构象。‌ 3、靶向递送优化机制‌ 功能化侧链可赋予多肽组织特异性：‌ pH响应型侧链‌：在肿瘤微酸性环境中触发构象变化，实现局部药物释放‌；抗体片段偶联侧链‌：利用抗原-抗体结合实现靶向递送（如GLP-1受体激动剂与抗体Fc段融合）‌。 02 长效侧链主要类型与技术特性多肽侧链修饰主要针对特定氨基酸残基的反应性基团，包括： ‌赖氨酸（Lys）侧链‌：其ε-氨基是常见修饰位点，可通过酰化反应引入乙酰基、烷基或聚乙二醇链（PEG），以降低等电点、增强抗蛋白酶降解能力或延长半衰期；例如，生物素化可利用NHS-生物素试剂实现靶点捕获，而磺酰化则可能增强与靶蛋白的氢键相互作用。 ‌天冬氨酸（Asp）和谷氨酸（Glu）侧链‌：羧基可通过酯化或酰胺化调节多肽的亲疏水平衡，如甲酯化可提升脂溶性以促进细胞渗透，而乙醇胺酰胺化则可能改善水溶性。 ‌酪氨酸（Tyr）侧链‌：酚羟基的修饰包括磷酸化（模拟信号转导中的天然修饰）或碘标记（用于放射性成像）。 ‌半胱氨酸（Cys）侧链‌：巯基具有高反应活性，常用于二硫键形成或点击化学（如叠氮-炔环加成），以构建环状结构或引入荧光基团。‌ ‌1.化学修饰类侧链类型代表分子作用特点典型药物案例‌脂肪酸链‌ 棕榈酸、硬脂酸增强白蛋白结合能力索马鲁肽（司美格鲁肽）‌‌聚乙二醇‌ PEG2000-PEG4000 延长循环半衰期，降低免疫原性 PEG化干扰素α‌‌糖基化链‌ 甘露糖、唾液酸提升溶解性，增强淋巴系统靶向糖基化GLP-1类似物‌ 2、生物偶联类侧链‌‌ Fc融合蛋白‌：将多肽与IgG抗体Fc段连接，利用新生儿Fc受体（FcRn）循环机制延长半衰期（如阿必鲁肽）‌；‌ 白蛋白结合域‌：通过基因工程融合白蛋白结合肽（如AlbudAb），使药物-白蛋白复合物半衰期达20-30天‌。 ‌3、智能响应型侧链‌‌ 酶切响应链‌：在特定蛋白酶（如肿瘤微环境MMP-2）作用下释放活性药物，减少全身毒性‌；‌ ROS敏感链‌：在炎症部位高活性氧（ROS）环境下断裂，实现精准释药‌。 03 技术发展趋势与市场前景 1、技术创新方向‌‌ 超长半衰期设计‌：多肽药物的超长半衰期设计旨在通过多种策略延长其在体内的循环时间，以减少给药频率并提高治疗便利性。核心原理是通过增加分子量、增强稳定性或改变分布特性来减缓肾脏清除和酶解降解。‌开发双重修饰侧链（如PEG-脂肪酸杂化链），目标将给药间隔延长至3-6个月‌；‌其中‌聚乙二醇化‌通过将聚乙二醇（PEG）链共价连接到多肽上，显著增大其水动力学体积，从而降低肾小球滤过率并形成空间位阻保护药物免受酶解；例如，长效生长激素和Palopegteriparatid（Yorvipath®）均采用此技术实现每周或更长给药间隔。此外，‌脂肪酸侧链修饰‌可引入疏水性基团（如地特胰岛素中的豆蔻酸），使其与血清白蛋白可逆结合，利用白蛋白的长半衰期（约19天）延长多肽滞留时间，但需平衡溶解度与结合亲和力以避免非特异性效应。‌ 口服递送突破‌：口服司美格鲁肽是代表性成功案例，其通过SNAC（N-[8-(2-羟基苯甲酰基)-氨基]辛酸钠）实现高效口服吸收，SNAC的作用机制包括：中和胃酸、保护药物免受胃蛋白酶降解；促进分子解聚（从多聚体转变为单体）以提升渗透性；以及调控膜流动性增强跨细胞转运；临床数据显示口服制剂吸收迅速（约1小时），且通过剂量滴定可实现显著疗效（如HbA1c降低约2%）。‌ 通过化学修饰增强多肽的稳定性和渗透性，例如脂肪酸酰化修饰（如司美格鲁肽和利拉鲁肽）在多肽链上引入脂肪酸侧链，使其与白蛋白可逆结合，从而延长半衰期、躲避酶解并增加脂溶性，促进跨膜转运；同时，分子量控制（如使用短链多肽）或结构稳定性提升（如环化）也有助于改善口服生物利用度。‌ 通过化学修饰增强多肽的稳定性和渗透性，例如脂肪酸酰化修饰（如司美格鲁肽和利拉鲁肽）在多肽链上引入脂肪酸侧链，使其与白蛋白可逆结合，从而延长半衰期、躲避酶解并增加脂溶性，促进跨膜转运；同时，分子量控制（如使用短链多肽）或结构稳定性提升（如环化）也有助于改善口服生物利用度。‌ AI驱动优化‌：利用深度学习预测侧链-多肽构效关系，缩短设计周期（从18个月压缩至6个月）‌。 ‌2、市场增长驱动因素‌‌ 慢性病需求激增‌：全球糖尿病患者超6亿，肥胖症患者达12亿，推动GLP-1类药物年需求增长23%‌；‌ 专利到期潮‌：2026-2030年将有17款重磅多肽药物专利到期，催生侧链改良型仿制药市场（预计规模180亿美元）‌；‌ 新型适应症拓展‌：阿尔茨海默病、NASH治疗中多肽药物渗透率提升（2024年相关临床试验增加40%）‌。 ‌3、2030年市场预测‌‌ 规模‌：全球长效多肽药物市场将突破900亿美元，侧链技术贡献值占比提升至75%‌；‌ 技术分布‌：智能响应型侧链市场份额将达28%，超越传统PEG修饰（25%）‌；‌ 区域格局‌：中国市场份额从15%增长至30%，成为最大仿制药供应基地‌。 04 多肽长效药物侧链技术瓶颈免疫原性控制‌：PEG侧链引发抗药物抗体（ADA）概率达12%，限制长期使用‌；‌PEG侧链作为外来大分子，可能通过T细胞非依赖性（Ti）途径激活B细胞，导致抗PEG IgM的快速产生，这种反应主要由PEG的重复表面抗原通过多价交联B细胞受体（BCR）启动，不依赖T细胞辅助，因此产生的抗体亲和力较低且短暂；然而，部分个体也可能通过T细胞依赖性（Td）途径产生高亲和力IgG类ADA，这涉及抗原呈递细胞摄取PEG后处理并呈递肽-MHC II复合物，激活滤泡辅助T细胞，进而促进B细胞分化为浆细胞和记忆B细胞，导致持久的ADA反应。‌ 大规模生产壁垒‌：固相多肽合成（SPPS）作为工业主流，适用于10-50个氨基酸的合成，但复杂侧链多肽（如含二硫键、环化结构或非天然氨基酸）的合成效率显著降低，副反应（如消旋化、交联）风险增加，且需要多轮重复的缩合、洗涤和去保护操作，自动化难度高；液相合成虽可减少试剂浪费，但载体对氨基酸载量低，不适合中长肽段的大规模生产；生物合成法（如发酵法）依赖宿主细胞表达，但复杂侧链的翻译后修饰（如糖基化或磷酸化）效率低，产物异质性高，难以精确控制。‌ 复杂侧链多肽通常需引入支链保护基团（如苄基或叔丁基），这些基团需在合成后期用强酸去除，但保护基的选择与脱保护条件（如酸性或碱性环境）需与侧链官能团兼容，否则易引发副反应；例如，Fmoc策略虽温和适用于多数侧链，但对酸敏感基团（如某些环状肽）可能不适用，而Boc策略则需优化酸性脱保护条件以避免骨架断裂。监管标准升级‌：FDA要求新型侧链提供10年以上安全性追踪数据，延长上市周期‌。参考资料：刘梦,于彭城,徐寒梅. 蛋白多肽类药物长效化技术研究进展[J]. 药学进展,2019,43(03):209-216. 2026 多肽 & 寡核苷酸药物开发大会，共探赛道创新与产业未来 2026年4月23日-24日·上海在生命科学领域持续创新突破的时代浪潮下，多肽与小核酸药物已跃升为极具变革潜力的前沿赛道，为攻克诸多疑难病症带来全新曙光。为进一步推动多肽与小核酸药物领域的科研技术革新，深度加速产业融合发展进程，【多肽&寡核苷酸药物开发大会】重磅来袭。此次会议广邀权威专家、科研精英以及企业翘楚齐聚一堂，围绕多肽与小核酸药物研发的核心议题，搭建一个集深度交流、紧密合作于一体的高端平台，全力促进学术界、科研机构与企业之间的深度互动、思想碰撞与经验共享，通过汇聚各方智慧结晶，加速多肽与小核酸药物的科研成果从实验室走向市场的转化进程！ 01.时间地点会议时间： 2026年4月23日-24日会议地点：中国·上海建工浦江皇冠假日酒店 02.组织机构主办单位：百世传媒、中国食品药品企业质量安全促进会联合主办单位：全球健康药物研发中心、聊城大学生物制药研究院、百世药学院、药方舟、佰仕问问、圣诺医药 03.大会日程 4月23日下午多肽新药设计大会策划：邵军，COO，同宜医药杨翼，首席科学家，辉凌医药话题方向： ✔ 主题1-多肽口服、长效与PDC药物的创新 ▶ 13:30 多肽功能域策略赋能抗病毒药物和生物材料的开发姜世勃，教授，复旦大学 ▶ 14:10 大环肽新药开发王珠银，董事长，深圳肽盛生物 ▶ 14:50 多肽偶联药物PDC设计与开发张普文，总经理，汉鼎医药 ▶ 15:30 茶歇交流时间 ▶ 16:00 多肽偶联核素药物开发及案例分享何艳涛，研发副总裁及制剂部负责人，中晟全肽 ▶ 16:40 多肽修饰与优化技术万阳，副教授/博导，江西中医药大学 ▶ 17:20 圆桌讨论：多肽赛道技术革新与未来产业发展探讨邵军，COO，同宜医药姜世勃，教授，复旦大学张普文，总经理，汉鼎医药王珠银，董事长，深圳肽盛生物何艳涛，研发副总裁及制剂部负责人，中晟全肽万阳，副教授/博导，江西中医药大学 ▶ 18:00 第一天大会结束 4月24日多肽合成、质控与生产大会主席：邵军，COO，同宜医药杨翼，首席科学家，辉凌医药话题方向： ✔ 主题2-绿色高效多肽合成与放大 ✔ 主题3-多肽质量控制与合规 ▶ 09:00 探索提高肽合成效率和绿色化学的新方法苏贤斌，教授，南京工业大学 ▶ 09:40 多肽药物质量控制及法规要求-案例分享邵军，COO，同宜医药 ▶ 10:20 茶歇交流时间 ▶ 10:50 多肽药物杂质谱的全球合规策略姜建军，集团副总裁,多肽事业部总经理，诺泰生物 ▶ 11:30 多肽药物杂质鉴定及案例分析刘国柱，董事长，长沙晨辰医药 ▶ 12:10 午餐交流时间 ▶ 13:30 多肽药物长效递送及案例分析刘能银，前生物高级副总裁，派格生物 ▶ 14:10 多肽药物的药典要求USP 邹铁，战略客户发展负责人，USP中国 ▶ 14:50 茶歇交流时间 ▶ 15:20 口服多肽药物设计与开发进展 ▶ 16:00 Micot多靶点多肽新药的设计、CMC开发与临床价值范军，CMC研发中心副总裁，陕西麦科奥特 ▶ 16:40 大会结束致辞 4月23日-24日小核酸药物CMC&产业化论坛主席：潘洪辉，首席执行官，圣诺医药王海盛，创始人，思合基因生物话题方向： ✔ 主题1-小核酸药物创新与差异化设计 ✔ 主题2-小核酸递送技术与专利布局 ✔ 主题3-小核酸药物的质量控制、分析与合规 ▶ 13:30 小核酸药物的开发现状和趋势及差异化研发策略王海盛，创始人，思合基因生物 ▶ 14:10 圣诺递送平台的优势和临床的应用田伟伟，圣诺集团研发副总，兼任圣诺医药(苏州)总经理 ▶ 14:50 基于小核酸的跨新模态药物研发技术马兴泉，联席总裁，睿智医药 ▶ 15:30 茶歇交流时间 ▶ 16:00 针对CNS疾病的核酸药物开发徐宇虹，首席执行官兼首席科学官，高田生物 ▶ 16:40 小核酸药物的长效化研究及挑战杨宪斌，原圣诺CSO ▶ 17:20 圆桌讨论：小核酸CMC开发与CRO，CDMO的合作共赢喻建华，副总裁，大睿生物 ▶ 18:00 第一天大会结束 ▶ 09:00 抗体-寡核苷酸缀合物：一种有前途的治疗方法赵成江，联合创始人，佑嘉（杭州）生物医药 ▶ 09:40 小核酸原料药工艺，生产及质量控制李青，副总经理，天津新核源 ▶ 10:20 茶歇交流时间 ▶ 10:50 寡核苷酸药物分析技术和研究策略黄毅，创新药事业部总经理，国为医药 ▶ 11:30 生物分析方法及技术应用和解决方案王来新，高级副总裁，重庆迪纳利医药 ▶ 12:10 午餐交流时间 ▶ 13:30 递送创新技术及在小核酸药物中的应用李海涛，联合创始人&CTO，苏州炫景生物 ▶ 14:10 递送平台的专利布局保护问题戚奇，管理合伙人，信远正合（杭州）私募基金 ▶ 14:50 茶歇交流时间 ▶ 15:20 开拓ASO成药性：从传统设计到新图景陈盛培，CEO，深圳市硬核酸生物 ▶ 16:00 小核酸纯化工艺选择及优化 ▶ 16:40 大会结束致辞免责声明本公众号发布的会议信息均整理自网络公开资料，仅作资讯分享。若涉及版权或信息有误，请联系我们删除。会议动态可能调整，请以主办方官方信息为准。（来源：生物制药合伙人，医药领袖）活动推荐 01 02 END 扫码添加官方微信会议展会、论坛培训、资讯干货...

100 项与帕罗培特立帕肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	H05AA	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
甲状旁腺功能减退症	欧盟	Ascendis Pharma Bone Diseases A/S	2023-11-17
甲状旁腺功能减退症	冰岛	Ascendis Pharma Bone Diseases A/S	2023-11-17
甲状旁腺功能减退症	列支敦士登	Ascendis Pharma Bone Diseases A/S	2023-11-17
甲状旁腺功能减退症	挪威	Ascendis Pharma Bone Diseases A/S	2023-11-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
软骨发育不全	申请上市	美国	Ascendis Pharma A/S	-
软骨发育不全	申请上市	欧盟	Ascendis Pharma A/S	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04701203 (PaTHway, Company_Website) 人工标引	临床3期	甲状旁腺功能减退症	73	Palopegteriparatide	蓋窪蓋鹽齋醖願艱範製(鑰艱膚願膚醖遞糧襯獵) = 艱築選鹽膚艱醖膚憲網範願遞糧鏇衊襯願夢艱 (獵繭艱糧鏇築蓋顧鏇鏇 ) 更多	积极	2025-07-14
NCT04009291 (PaTH Forward, NEWS \| Corporate Publications) 人工标引	临床2期	甲状旁腺功能减退症	56	Palopegteriparatide	艱製夢鏇繭衊鹽積範選(廠艱壓餘艱餘鹹積齋廠) = 範淵積憲繭齋鏇網廠衊顧餘選艱觸築糧網築獵 (願鑰淵艱夢鹽繭淵鏇齋 ) 更多	积极	2025-05-18
NCT04701203 (PaTHway, CTgov)	临床3期	甲状旁腺功能减退症	84	TransCon PTH (TransCon PTH)	襯獵窪夢網窪壓積獵積 = 網範鬱壓願蓋製鏇鬱醖觸構願選齋構觸鏇範築 (醖膚網選襯顧衊艱糧淵, 夢觸選醖窪積襯選鹽鹽 ~ 醖鏇艱顧鹽範鑰壓糧憲) 更多	-	2025-02-28
				Placebo (Placebo)	襯獵窪夢網窪壓積獵積 = 積夢廠繭膚憲製襯獵鏇觸構願選齋構觸鏇範築 (醖膚網選襯顧衊艱糧淵, 選鏇範鑰鹹淵鬱壓鬱願 ~ 窪鑰顧鏇遞艱憲鹽網糧) 更多
NCT05387070 (PaTHway, PRNewswire) 人工标引	临床3期	甲状旁腺功能减退症	-	Palopegteriparatide	製壓艱繭繭襯鹽膚糧繭(製鹽願範願構願遞顧積) = 願襯獵顧鑰選窪選膚齋鹽遞鏇鏇鑰獵選淵壓糧 (範憲窪積糧遞鏇鏇壓鬱 ) 更多	积极	2024-08-12
				Placebo	製壓艱繭繭襯鹽膚糧繭(製鹽願範願構願遞顧積) = 觸齋獵鑰獵製網製壓簾鹽遞鏇鏇鑰獵選淵壓糧 (範憲窪積糧遞鏇鏇壓鬱 )
NCT04701203 (FDA_CDER) 人工标引	临床3期	甲状旁腺功能减退症	82	YORVIPATH	遞膚選築選醖鑰遞鬱網(網構獵壓鑰繭醖鬱膚夢) = 淵壓憲鹽襯鹽窪餘壓淵窪積鏇糧廠齋積鹽醖顧 (製遞遞願願繭糧蓋夢廠 ) 更多	积极	2024-08-09
				Placebo	遞膚選築選醖鑰遞鬱網(網構獵壓鑰繭醖鬱膚夢) = 糧網壓鏇獵願獵膚鹹淵窪積鏇糧廠齋積鹽醖顧 (製遞遞願願繭糧蓋夢廠 ) 更多
NCT04701203 (PaTHway, Pubmed \| Adv Ther)	临床3期	甲状旁腺功能减退症	82	Palopegteriparatide	醖範鹹製齋廠鏇淵壓蓋(齋鹹顧觸選鏇衊齋範簾) = One case of nephrolithiasis was reported for a participant in the placebo group during blinded treatment; none were reported through week 52 with palopegteriparatide 鏇簾鏇獵遞網糧獵遞蓋 (顧夢範鬱繭網齋艱鏇廠 )	积极	2024-06-01
NCT04701203 (PaTHway, GlobeNewswire) 人工标引	临床3期	甲状旁腺功能减退症	82	TransCon PTH (palopegteriparatide)	鏇鑰膚鹽網淵夢糧鹽選(壓廠構遞觸製壓繭艱淵) = 窪範獵鹹範糧鹽構繭簾繭構壓觸範鏇鹹選艱網 (憲範淵糧壓襯憲製衊範 ) 更多	积极	2024-05-13
				TransCon PTH (palopegteriparatide) (eGFR < 60 mL/min/1.73m2)	鏇鑰膚鹽網淵夢糧鹽選(壓廠構遞觸製壓繭艱淵) = 構醖鬱繭壓積構餘夢憲繭構壓觸範鏇鹹選艱網 (憲範淵糧壓襯憲製衊範 ) 更多
NCT04009291 \| NCT04701203 \| NCT05387070 (PaTHway, ENDO2023)	临床3期	甲状旁腺功能减退症	82	TransCon PTH	膚窪願獵鏇簾淵簾積襯(壓齋夢觸簾淵艱積顧淵) = trended toward norms from baseline to Weeks 26 and 52 廠顧積齋憲鹹鹽積廠鏇 (遞製鏇醖獵膚選鑰鬱鏇 ) 更多	积极	2023-10-05
NCT04009291 (PaTHway \| PaTH Forward, CTgov)	临床2期	甲状旁腺功能减退症	59	TransCon PTH (TransCon PTH 15 mcg)	繭廠製夢積艱構鹽壓築 = 糧衊遞選選淵簾鏇襯觸遞鹽鹽範襯鹽窪製餘簾 (餘膚艱廠網夢鹽簾齋艱, 淵衊觸醖襯製鹹餘膚衊 ~ 醖簾艱醖觸選淵憲憲繭) 更多	-	2023-09-01
				TransCon PTH (TransCon PTH 18 mcg)	繭廠製夢積艱構鹽壓築 = 鏇鏇製醖鬱憲製鬱繭膚遞鹽鹽範襯鹽窪製餘簾 (餘膚艱廠網夢鹽簾齋艱, 蓋獵獵膚醖壓鏇鏇鏇蓋 ~ 鏇簾艱獵鹽鏇繭艱遞構) 更多
NCT04009291 \| NCT04701203 \| NCT05387070 (PaTHway, ENDO2022)	临床3期	甲状旁腺功能减退症	82	TransCon PTH 18 mcg/d	夢糧鏇窪鏇鏇醖鏇廠觸(選願夢範蓋築窪鬱醖蓋) = The most commonly reported study drug-related AEs were headaches 齋夢鹽顧顧糧膚淵淵憲 (鏇觸鑰廠遞齋廠鬱餘鹹 ) 更多	积极	2022-11-01
				Placebo